Friday, December 18, 2009

Regenerative Medicines: Bone and Joint Applications

According to a new technical market research report, REGENERATIVE MEDICINES: BONE AND JOINT APPLICATIONS (PHM032B) from BCC Research (, the value of the global market for regenerative medicines is an estimated $1.2 billion in 2009, but is expected to increase to $1.8 billion in 2014, for a 5-year compound annual growth rate (CAGR) of 8.6%.

The largest segment of the market, bone replacement/grafting, is projected to grow at a CAGR of 6.3% to reach $979 million in 2014. Its value is estimated at $721 million in 2009.

Bone growth stimulators, the second-largest segment, is estimated at $330 million in 2009, and is expected to increase at a 5-year CAGR of 11.9% to reach $578 million in 2014.

The smallest segment, tissue engineering/cartilage, is projected to reach $207 million in 2014, after rising at a CAGR of 12.5% from the 2009 estimate of $115 million.

Regenerative medicine is an area of research and product development that shows great promise in treating or curing diseases and conditions that currently have limited or no treatment options, such as blindness, deafness, bone and cartilage damage, neurodegeneration, diabetes, and heart disease. Although science is still a long way from regrowing new limbs or organs, stem cell research and its applications in regenerative medicine currently offer an opportunity to develop the first generation of therapeutics to do what has never before seemed possible.

The principal focus in this report is on bone and joint applications; however, other regenerative applications such as dental, neurologic, organ regeneration, cardiovascular, urologic, diabetes, and wound care are important. The study provides a comprehensive analysis of the current markets for regenerative medicine products, relevant applications, and the potential of products in development.

The information and analysis presented are important assets in decision making for managers involved in business development, marketing, market research, product development, mergers and acquisitions, licensing, business management, investment banking, and deal creation, as well as to consultants to the pharmaceutical and biotechnology industries.

No comments:

Post a Comment

Bookmark and Share